Effects of intrathecal baclofen on voluntary motor control in spastic paresis.

Intrathecal baclofen injections were given to six patients with long-standing spastic paresis resistant to any nondestructive treatment, including oral baclofen. Attempts by the patients at voluntary muscle activation before intrathecal administration of baclofen led to considerable uncontrolled coactivation of antagonist and distant muscles. After the injection, dramatic suppression of the spastic signs was accompanied by more selective voluntary muscle activation. Tonic coactivation of the antagonists and distant muscle groups during voluntary contractions was decreased while the agonist level on electromyography (EMG) was not affected (three cases) or only slightly reduced (three cases). Furthermore, in one patient with sufficient residual motor control function, there was a considerable increase in the speed of fast isotonic movements, accompanied by the emergence of the ability to generate phasic muscle bursts on EMG that were characteristic of normal motor patterns. The results suggest that baclofen exerts different effects upon reflex pathways and descending motor pathways. This therapy appears to be a promising way for improving residual motor control in patients with increased muscle tone and/or reflexes.

[1]  J. Vanneste,et al.  Intrathecal baclofen for treatment of spasticity. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[2]  M. Latash,et al.  Intrathecal Baclofen for Severe Spinal Spasticity , 1989, The New England journal of medicine.

[3]  M. Latash,et al.  Short-term effects of intrathecal baclofen in spasticity , 1989, Experimental Neurology.

[4]  R. Penn,et al.  Long-term intrathecal baclofen infusion for treatment of spasticity. , 1987, Journal of neurosurgery.

[5]  D. Corcos,et al.  Movement deficits caused by hyperexcitable stretch reflexes in spastic humans. , 1986, Brain : a journal of neurology.

[6]  R. Penn,et al.  CONTINUOUS INTRATHECAL BACLOFEN FOR SEVERE SPASTICITY , 1985, The Lancet.

[7]  N. Bowery,et al.  GABA receptor multiplicity Visualization of different receptor types in the mammalian CNS , 1984, Neuropharmacology.

[8]  G. Wilkin,et al.  Are baclofen-sensitive GABAB receptors present on primary afferent terminals of the spinal cord? , 1984, Nature.

[9]  J. Davies,et al.  SELECTIVE DEPRESSION OF SYNAPTIC EXCITATION IN CAT SPINAL NEURONES BY BACLOFEN: AN IONTOPHORETIC STUDY , 1981, British journal of pharmacology.

[10]  R. Angel,et al.  Impairment of voluntary movement by spasticity , 1979, Annals of neurology.

[11]  R. A. Davidoff,et al.  Pharmacology of spasticity , 1978, Neurology.

[12]  S. Sahrmann,et al.  The relationship of voluntary movement of spasticity in the upper motor neuron syndrome , 1977, Transactions of the American Neurological Association.

[13]  Landau Wm Editorial: Spasticity: the fable of a neurological demon and the emperor's new therapy. , 1974 .

[14]  F. Pierau,et al.  Action of a GABA-derivative on postsynaptic potentials and membrane properties of cats' spinal motoneurones. , 1973, Brain research.

[15]  H. Dodd Needles for Varicose Veins , 1948, British medical journal.

[16]  R. Penn,et al.  Functional outcome after delivery of intrathecal baclofen. , 1989, Archives of physical medicine and rehabilitation.

[17]  D Burke,et al.  Spasticity as an adaptation to pyramidal tract injury. , 1988, Advances in neurology.

[18]  R. Penn Chronic Intrathecal Baclofen for Severe Rigidity and Spasms , 1988 .

[19]  D. Dralle,et al.  Intrathecal Baclofen in Spasticity , 1988 .

[20]  E. Knutsson Analysis of gait and isokinetic movements for evaluation of antispastic drugs or physical therapies. , 1983, Advances in neurology.

[21]  R. Young,et al.  Spasticity, disordered motor control , 1980 .

[22]  Norton Bj,et al.  The relationship of voluntary movement to spasticity in the upper motor neuron syndrome. , 1977 .

[23]  W. Landau Editorial: Spasticity: the fable of a neurological demon and the emperor's new therapy. , 1974, Archives of neurology.